【摘要】 目的:比较米氮平与阿米替林治疗阿尔茨海默病(AD)所致抑郁患者的临床疗效和安全性。方法:诊断为AD抑郁患者60例,随机分为A、B 2组各30例,分别采用米氮平与阿米替林治疗8周。采用汉密尔顿抑郁量表(HAMD)和副反应量表(TESS)于治疗前和治疗后2、4、6、8周末时分别评定疗效和副反应。结果:A组和B组显效率分别为83.0%和70.0%,疗效相仿;HAMD评分,A组在治疗2周末即显著下降(P<0.01),B组在第4周才明显下降(P<0.05);8周末2组差异无显著性意义。副反应A组明显少于和轻于B组(P<0.01)。结论:米氮平治疗AD抑郁安全性高、副反应轻微,且见效快。更多还原

【Abstract】 Objective: To compare the efficacy and security of mirtazapine and amitriptyline in the treatment of depression induced by Alzheimer disease(AD).Methods: Sixty patients with depression induced by AD were randomly into the treatment groups of mirtazapine or amitriptyline for 8 weeks.Clinical progress was examined with HAMD and TESS.Results: The effective rates of mirtazapine and amitriptyline were 83.0 % and 70.0 % respectively with the difference being not significant between two groups.There was no significant difference in the scores of HAMD between two groups at the end of 8 weeks.The scores of HAMD were decreased significantly at the end of the second week in mirtazapine group,but did at the end of the fourth week in amitriptyline group.The side effects of mirtazapine were fewer and milder than those of amitriptyline. Conclusion: Mirtazapine is an effective and safe drug in the treatment of depression associated with AD.更多还原